ClinicalTrials.gg
CompletedNCT02200770Updated Dec 3, 2021Results posted

N-MOmentum: A Clinical Research Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorders

A Phase 2/3 interventional study of Inebilizumab and Placebo in Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders, sponsored by MedImmune LLC. Completed at 98 sites in 25 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-12-03.

Sponsored by MedImmune LLC (part of AstraZeneca) · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
231
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies in Neuromyelitis Optica by AstraZeneca — 3 open to participants now, 5 under way, 3 of them phase 3. Neuromyelitis Optica · AstraZeneca.

Started
2015
with 1 other
Phase 2/3
3 of 11
none open now
Registered
3rd of 11
by date

Among the 11 studies in Neuromyelitis Optica by AstraZeneca, this one is one of 2 that started in 2015, is one of 3 in phase 2/3, and was the 3rd registered.

Neuromyelitis Optica

178 studies on the registry are indexed under Neuromyelitis Optica; 78 are open to participants now.

Browse Neuromyelitis Optica studies →

Open to participants now

3 of the 11 studies in Neuromyelitis Optica by AstraZeneca are open now, in 11 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 50 Neuromyelitis Optica studies recruiting now, 29 (58%) set no upper age limit and 16 (32%) stop at 75 or younger; 11 take children under 18; 9 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Neuromyelitis Optica by AstraZeneca, or all of them as a file.
02

Study summary

To compare the efficacy of inebilizumab (MEDI-551) versus placebo in reducing the risk of an neuromyelitis optica/neuromyelitis optica- spectrum disorders (NMO/NMOSD) attack in participants with NMO/NMOSD.

Read the detailed description

Inebilizumab is a genetically engineered humanized monoclonal antibody that binds to the B cell specific surface antigen cluster of differentiation (CD19) resulting in the depletion of B cells. Inebilizumab depletes antibody-secreting plasmablasts and some plasma cells, which are generally CD19 positive and CD20 negative.

The main objective of this study is to determine whether inebilizumab compare to placebo decreases the risk of an attack in participants with NMO/NMOSD.

This is a multicenter, multinational, randomized, double-masked, placebo controlled study with an open-label extension period to evaluate the efficacy and safety of intravenous (IV) inebilizumab in adult participants with NMO/NMOSD. After a screening period, eligible participants will enter a randomized-controlled period (RCP) of maximum 197 days where they will be randomized in a 3:1 ratio to receive either IV inebilizumab or placebo. NMO/NMOSD attacks will be evaluated by the investigator and confirmed against the attack criteria by an independent Adjudication Committee (AC). Participants for whom the attack was confirmed by the AC will be given the option to enroll into an open label period (OLP) with inebilizumab treatment. Participants who complete the RCP without experiencing an attack will be given the option to enroll into an OLP with inebilizumab treatment. The OLP will continue for a minimum of 1 year and a maximum of 3 years after the last participant enter the OLP. All participants who discontinue from the RCP or the OLP will continue in a Safety Follow-up for a total of 12 months from last dose to evaluate the long-term safety of the investigational product.

03

Conditions studied

  • Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders

Keywords

  • NMO, NMOSD, Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorders, autoimmune, demyelination, MEDI-551, monoclonal antibody, Devic's syndrome, B-cell
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Men and women 18 years or older with diagnosis of NMO/NMOSD
  2. Confirmation of NMO/NMOSD status:

    1. AQP4-IgG sero-positive NMO/NMOSD with at least one attack requiring rescue therapy in the last year or two attacks requiring rescue therapy in the last 2 years
    2. AQP4-IgG sero-negative NMO with at least one attack requiring rescue therapy in the last year or two attacks requiring rescue therapy in the last 2 years
  3. Able and willing to give written and comply with the requirements of the study protocol.
  4. EDSS \<= 7.5 (8 in special circumstances)
  5. Men and women of must agree to use a highly effective method of from screening to 6 months after final dose of the product.

Exclusion criteria

Exclusion Criteria:

  1. Lactating and pregnant females
  2. Treatment with any agent within 4 weeks of screening
  3. Known history of a severe allergy or reaction to any component of the investigational product formulation or history of anaphylaxis following any biologic therapy.
  4. Known active severe bacterial, viral, or other infection or any major episode of infection requiring hospitalization.
  5. History of alcohol, drug, or chemical abuse, or a recent history of such abuse \< 1 year prior to randomization
  6. Receipt of the following at any time prior to randomization:

    1. Alemtuzumab
    2. Total lymphoid irradiation
    3. Bone marrow transplant
    4. T-cell vaccination therapy
  7. Receipt of rituximab or any experimental B-cell depleting agent within 6 months prior screening and B-cells below the lower limit of normal.
  8. Receipt of intravenous immunoglobulin (IVIG) within 1 month prior to randomization.
  9. Receipt of any of the following within 3 months prior to randomization:

    1. Natalizumab (Tysabri®).
    2. Cyclosporin
    3. Methotrexate
    4. Mitoxantrone
    5. Cyclophosphamide
    6. Tocilizumab
    7. Eculizumab
  10. History of and/or (Hep B/C at screening)
  11. Known history of a primary immunodeficiency (congenital or acquired) or an underlying condition such as (HIV) infection
  12. History of , apart from squamous cell or basal cell carcinoma of the skin treated with documented success of curative therapy > 3 months prior to randomization
  13. Any concomitant disease other than NMO/NMOSD that required treatment with oral or intravenous at doses over 20 mg a day for over 21 days
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
231 participants (actual)

Study arms

  • Placebo comparator
    Placebo/Inebilizumab

    Aquaporin-4-antibody (AQP4-IgG) sero positive and sero negative participants will receive IV dose of placebo matched to inebilizumab on Day 1 and Day 15 of the RCP. The participants who enter OLP will receive IV inebilizumab 300 mg on both Day 1 and Day 15, followed by a single IV dose of inebilizumab 300 mg every 6 months until maximum of 3 years after the last participant enters the OLP. Participants will have choice to enter in the SFP at any point during RCP or OLP and will be free to pursue other treatment options otherwise prohibited during the RCP and OLP. Participants will continue in the SFP for 12 months from last dose of study drug.

    Drug: Inebilizumab · Other: Placebo

  • Experimental
    Inebilizumab/Inebilizumab

    AQP4-IgG sero positive and sero negative participants will IV dose of inebilizumab 300 mg on Day 1 and Day 15 of RCP. The participants who enter OLP will receive IV inebilizumab 300 mg on Day 1 and matching placebo on Day 15, followed by a single IV dose of inebilizumab 300 mg every 6 months until maximum of 3 years after the last participant enters the OLP. Participants will have choice to enter in the SFP at any point during RCP or OLP and will be free to pursue other treatment options otherwise prohibited during the RCP and OLP. Participants will continue in the SFP for 12 months from last dose of study drug.

    Drug: Inebilizumab · Other: Placebo

Interventions

  • Participants will receive IV inebilizumab 300 mg.

    Also known as: MEDI-551

  • OtherPlacebo

    Participants will receive IV placebo matched to inebilizumab.

06

What researchers measure

Primary outcomes

  1. Time to Adjudication Committee (AC)-Determined Neuromyelitis Optica Spectrum Disorder (NMOSD) Attack During RCP

    The NMOSD attack is defined as the presence of new or worsening symptom(s) related to NMOSD that meet at least one of the 18 protocol-defined attack criteria. These criteria were developed in conjunction with a panel of disease experts and with Food and Drug Administration input, and were intended to be clinically meaningful, objective, quantifiable, and able to be used worldwide. Only attacks positively adjudicated by the AC were used for the primary analysis.

    Time frame: Day 1 (Baseline) through Day 197

Secondary outcomes

  1. Percentage of Participants With Worsening in Expanded Disability Severity Scale (EDSS) Score From Baseline to the Last Visit of RCP

    EDSS and its associated functional system (FS) score provide a system for quantifying disability and monitoring changes in the level of disability over time. EDSS is a scale for assessing neurologic impairment in multiple sclerosis (MS). It consists of 7 FS (visual FS, brainstem FS, pyramidal FS, cerebellar FS, sensory FS, bowel and bladder FS, and cerebral FS) which are used to derive EDSS score ranging from 0 (normal neurological exam) to 10 (death from MS). A negative change from baseline indicates improvement. A participant was considered to have a worsening in overall EDSS score of at least 2 if baseline EDSS score was 0, or at least 1 point if baseline EDSS score is 1 to 5, or at least 0.5 point if baseline EDSS score is 5.5 or more.

    Time frame: Day 1 (Baseline) through Day 197

  2. Change From Baseline in Low-Contrast Visual Acuity Binocular Score to the Last Visit of RCP

    Low-contrast visual acuity test is used to determine the number of letters that can be read on a standardized low-contrast Landolt C Broken Rings Chart held at a distance of 3 meters. Binocular score is the number of letters read correctly on an eye chart using both eyes simultaneously. The total score ranges from 0-70. Higher score indicates better vision.

    Time frame: Day 1 (Baseline) through Day 197

  3. Cumulative Number of Active Magnetic Resonance Imaging (MRI) Lesions During RCP

    The number of new gadolinium-enhancing lesions and new or enlarging T2 lesions were measured by MRI of the brain, optic nerve, and spinal cord.

    Time frame: From Screening (Day -28) to Day 197

  4. Number of NMOSD-related In-patient Hospitalizations During RCP

    Participants with relapsing NMOSD have recurrent attacks that can be severe and result in blindness, paralysis, and even death and consequently, such attacks frequently result in in-patient hospitalizations. In-patient hospitalization is defined as a stay in hospital that goes beyond midnight of the first day of admission.

    Time frame: Day 1 (Baseline) through Day 197

  5. Annualized AC-determined NMOSD Attack Rate During Any Exposure to Inebilizumab

    Annualized attack rate is defined as total number of AC-determined attacks divided by total person years. Total person-years is calculated as the sum of the person-years for individual participant. Person-year for individual participant = (Date of last day before safety follow-up period - first inebilizumab dose date +1)/365.25. Annualized AC-determined NMOSD attack rate during any exposure to inebilizumab (in RCP and OLP) is reported.

    Time frame: For participants randomized to inebilizumab: Day 1 of RCP through end of OLP (approximately 3.5 years); and for participants randomized to placebo: Day 1 of OLP through the end of OLP (approximately 3 years)

  6. Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs) During RCP

    An adverse event (AE) is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Serious adverse event is any AE that resulted in death, life threatening, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, is a congenital anomaly/birth defect in offspring of a study participant, is an important medical event that may jeopardize the participant or may require medical intervention. TEAEs are defined as events present at baseline that worsened in intensity after administration of study drug or events absent at baseline that emerged after administration of study drug during the RCP.

    Time frame: Day 1 (Baseline) through Day 197

  7. Number of Participants With TEAEs and TESAEs During OLP

    An AE is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Serious adverse event is any AE that resulted in death, life threatening, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, is a congenital anomaly/birth defect in offspring of a study participant, is an important medical event that may jeopardize the participant or may require medical intervention. TEAEs are defined as events present at baseline that worsened in intensity after administration of study drug or events absent at baseline that emerged after administration of study drug during the OLP.

    Time frame: Day 198 through end of OLP period (maximum of 3 years after the last participant entered, until regulatory approval or study discontinuation, whichever occurs first) (approximately 3 years)

  8. Number of Participants With TEAEs and TESAEs During SFP (Open-label Population)

    An AE is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Serious adverse event is any AE that resulted in death, life threatening, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, is a congenital anomaly/birth defect in offspring of a study participant, is an important medical event that may jeopardize the participant or may require medical intervention. TEAEs are defined as events present at baseline that worsened in intensity after administration of study drug or events absent at baseline that emerged after administration of study drug during the OLP. Participant who prematurely discontinued from the RCP or OLP entered in the SFP.

    Time frame: Every 3 months for a total of 1 year after the last dose of study drug (approximately 3 years)

  9. Number of Participants With TEAEs and TESAEs During SFP (Non-OLP Population)

    An AE is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Serious adverse event is any AE that resulted in death, life threatening, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, is a congenital anomaly/birth defect in offspring of a study participant, is an important medical event that may jeopardize the participant or may require medical intervention. TEAEs are defined as events present at baseline that worsened in intensity after administration of study drug or events absent at baseline that emerged after administration of study drug during the OLP. The SFP started when a participant prematurely discontinues from the RCP or OLP.

    Time frame: Every 3 months for a total of 1 year after the last dose of study drug (approximately 3 years)

  10. Number of Participants With at Least a 2-Grade Shift From Baseline to Worst Toxicity Grade in Hematology and Chemistry During RCP

    Number of participants with at least a 2-grade shift from baseline to worst toxicity grade in hematology and chemistry during RCP is reported.

    Time frame: Day 1 (Baseline) through Day 197

  11. Number of Participants With at Least a 2-Grade Shift From Baseline to Worst Toxicity Grade in Hematology and Chemistry During OLP

    Number of participants with at least a 2-grade shift from baseline to worst toxicity grade in hematology and chemistry during OLP is reported.

    Time frame: Day 198 through end of OLP (maximum of 3 years after the last participant enters, until regulatory approval or study discontinuation, whichever occurs first) (approximately 3 years)

  12. Time to Maximum Serum Concentration (Tmax) of Inebilizumab (During RCP)

    Time to maximum serum concentration of inebilizumab during RCP is reported.

    Time frame: Dose 1 (Pre and post dose on Day 1 and Day 8); and Dose 2 (pre and post dose on Day 15; and Days 29, 57, 85, 113, 155, and 197)

  13. Maximum Observed Serum Concentration (Cmax) of Inebilizumab (During RCP)

    Maximum observed serum concentration of inebilizumab during RCP is reported.

    Time frame: Dose 1 (Pre and post dose on Day 1 and Day 8); and Dose 2 (pre and post dose on Day 15; and Days 29, 57, 85, 113, 155, and 197)

  14. Area Under the Serum Concentration Time Curve of the Dosing Interval (AUC0-14d) of Inebilizumab (During RCP)

    Area under the serum concentration time curve of the dosing interval (AUC0-14d) of inebilizumab during RCP is reported.

    Time frame: Dose 1 (Pre and post dose on Day 1 and Day 8); and Dose 2 (pre and post dose on Day 15; and Days 29, 57, 85, 113, 155, and 197)

  15. Number of Participants With Positive Anti-Drug Antibodies (ADA) Titer to Inebilizumab (During RCP)

    Number of participants with positive ADA titer to inebilizumab during RCP is reported.

    Time frame: Pre and post dose on Day 1; and on Days 29, 85, and 197

  16. Number of Participants With Positive Anti-Drug Antibodies (ADA) Titer to Inebilizumab (During OLP)

    Number of participants with positive ADA titer to inebilizumab in OLP is reported.

    Time frame: Pre and post dose on Day 1; and on Days 92, 183, 274, and then every 6 months (maximum of 3 years after the last participant enters, until regulatory approval or study discontinuation, whichever occurs first) (approximately 3 years)

07

Results

Posted Dec 26, 2019
Limitations and caveats
In the safety follow-up period (SFP), only 1 participant from 'Placebo/Inebilizumab' arm rolled over to SFP and no participant from 'Inebilizumab /Inebilizumab' arm rolled over to SFP. For EudraCT result posting, a study period with any one of the arm with zero participants started is not acceptable (EudraCT limitation). Therefore, not included SFP in 'Participant Flow' section to keep the data consistent across registry portals.

Participant flow

Randomized-controlled Period (RCP)
Participant flow — Randomized-controlled Period (RCP)
MilestonePlacebo/InebilizumabInebilizumab/Inebilizumab
Started56175
Treated56174
Completed54169
Not completed26
Withdrew: Adverse event02
Withdrew: Withdrawal by subject11
Withdrew: Participants randomized, but not treated01
Withdrew: Other12
Open-label Period (OLP)
Participant flow — Open-label Period (OLP)
MilestonePlacebo/InebilizumabInebilizumab/Inebilizumab
Started51165
Completed43131
Not completed834
Withdrew: Adverse event12
Withdrew: Death12
Withdrew: Lost to follow-up01
Withdrew: Withdrawal by subject014
Withdrew: Other615

Outcome measures

PrimaryTime to Adjudication Committee (AC)-Determined Neuromyelitis Optica Spectrum Disorder (NMOSD) Attack During RCP

The NMOSD attack is defined as the presence of new or worsening symptom(s) related to NMOSD that meet at least one of the 18 protocol-defined attack criteria. These criteria were developed in conjunction with a panel of disease experts and with Food and Drug Administration input, and were intended to be clinically meaningful, objective, quantifiable, and able to be used worldwide. Only attacks positively adjudicated by the AC were used for the primary analysis.

Time frame:
Day 1 (Baseline) through Day 197
Reported as:
Median · Days
Time to Adjudication Committee (AC)-Determined Neuromyelitis Optica Spectrum Disorder (NMOSD) Attack During RCP
DaysPlacebo/InebilizumabInebilizumab/Inebilizumab
Time to Adjudication Committee (AC)-Determined Neuromyelitis Optica Spectrum Disorder (NMOSD) Attack During RCPNA (142.0 to NA)NA (NA to NA)
Statistical analysis
  • Placebo/Inebilizumab vs Inebilizumab/Inebilizumab · Regression, Cox · p = <0.0001 · Hazard ratio (hr): 0.272 · 95% CI 0.1496 to 0.4961
SecondaryPercentage of Participants With Worsening in Expanded Disability Severity Scale (EDSS) Score From Baseline to the Last Visit of RCP

EDSS and its associated functional system (FS) score provide a system for quantifying disability and monitoring changes in the level of disability over time. EDSS is a scale for assessing neurologic impairment in multiple sclerosis (MS). It consists of 7 FS (visual FS, brainstem FS, pyramidal FS, cerebellar FS, sensory FS, bowel and bladder FS, and cerebral FS) which are used to derive EDSS score ranging from 0 (normal neurological exam) to 10 (death from MS). A negative change from baseline indicates improvement. A participant was considered to have a worsening in overall EDSS score of at least 2 if baseline EDSS score was 0, or at least 1 point if baseline EDSS score is 1 to 5, or at least 0.5 point if baseline EDSS score is 5.5 or more.

Time frame:
Day 1 (Baseline) through Day 197
Reported as:
Number · Percentage of Participants
Percentage of Participants With Worsening in Expanded Disability Severity Scale (EDSS) Score From Baseline to the Last Visit of RCP
Percentage of ParticipantsPlacebo/InebilizumabInebilizumab/Inebilizumab
Percentage of Participants With Worsening in Expanded Disability Severity Scale (EDSS) Score From Baseline to the Last Visit of RCP33.914.9
Statistical analysis
  • Placebo/Inebilizumab vs Inebilizumab/Inebilizumab · Regression, Logistic · p = 0.0033 · Odds ratio (or): 0.352 · 95% CI 0.1755 to 0.7059
SecondaryChange From Baseline in Low-Contrast Visual Acuity Binocular Score to the Last Visit of RCP

Low-contrast visual acuity test is used to determine the number of letters that can be read on a standardized low-contrast Landolt C Broken Rings Chart held at a distance of 3 meters. Binocular score is the number of letters read correctly on an eye chart using both eyes simultaneously. The total score ranges from 0-70. Higher score indicates better vision.

Time frame:
Day 1 (Baseline) through Day 197
Reported as:
Least squares mean · Score on scale
Change From Baseline in Low-Contrast Visual Acuity Binocular Score to the Last Visit of RCP
Score on scalePlacebo/InebilizumabInebilizumab/Inebilizumab
Change From Baseline in Low-Contrast Visual Acuity Binocular Score to the Last Visit of RCP1.442 ± 1.2171.576 ± 0.935
Statistical analysis
  • Placebo/Inebilizumab vs Inebilizumab/Inebilizumab · ANCOVA · p = 0.9026 · Mean difference (net): 0.134 · 95% CI -2.0254 to 2.2941
SecondaryCumulative Number of Active Magnetic Resonance Imaging (MRI) Lesions During RCP

The number of new gadolinium-enhancing lesions and new or enlarging T2 lesions were measured by MRI of the brain, optic nerve, and spinal cord.

Time frame:
From Screening (Day -28) to Day 197
Reported as:
Mean · Number of lesions
Cumulative Number of Active Magnetic Resonance Imaging (MRI) Lesions During RCP
Number of lesionsPlacebo/InebilizumabInebilizumab/Inebilizumab
Cumulative Number of Active Magnetic Resonance Imaging (MRI) Lesions During RCP2.3 ± 1.31.6 ± 1.0
Statistical analysis
  • Placebo/Inebilizumab vs Inebilizumab/Inebilizumab · Negative Binomial Regression · p = 0.0034 · Rate ratio: 0.566 · 95% CI 0.3866 to 0.8279
SecondaryNumber of NMOSD-related In-patient Hospitalizations During RCP

Participants with relapsing NMOSD have recurrent attacks that can be severe and result in blindness, paralysis, and even death and consequently, such attacks frequently result in in-patient hospitalizations. In-patient hospitalization is defined as a stay in hospital that goes beyond midnight of the first day of admission.

Time frame:
Day 1 (Baseline) through Day 197
Reported as:
Mean · Number of In-patient Hospitalizations
Number of NMOSD-related In-patient Hospitalizations During RCP
Number of In-patient HospitalizationsPlacebo/InebilizumabInebilizumab/Inebilizumab
Number of NMOSD-related In-patient Hospitalizations During RCP1.4 ± 0.71.0 ± 0
Statistical analysis
  • Placebo/Inebilizumab vs Inebilizumab/Inebilizumab · Negative Binomial Regression · p = 0.0146 · Rate ratio: 0.317 · 95% CI 0.1257 to 0.7972
SecondaryAnnualized AC-determined NMOSD Attack Rate During Any Exposure to Inebilizumab

Annualized attack rate is defined as total number of AC-determined attacks divided by total person years. Total person-years is calculated as the sum of the person-years for individual participant. Person-year for individual participant = (Date of last day before safety follow-up period - first inebilizumab dose date +1)/365.25. Annualized AC-determined NMOSD attack rate during any exposure to inebilizumab (in RCP and OLP) is reported.

Time frame:
For participants randomized to inebilizumab: Day 1 of RCP through end of OLP (approximately 3.5 years); and for participants randomized to placebo: Day 1 of OLP through the end of OLP (approximately 3 years)
Reported as:
Number · Annualized attack rate
Annualized AC-determined NMOSD Attack Rate During Any Exposure to Inebilizumab
Annualized attack rateAny Inebilizumab
Annualized AC-determined NMOSD Attack Rate During Any Exposure to Inebilizumab0.086
SecondaryNumber of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs) During RCP

An adverse event (AE) is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Serious adverse event is any AE that resulted in death, life threatening, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, is a congenital anomaly/birth defect in offspring of a study participant, is an important medical event that may jeopardize the participant or may require medical intervention. TEAEs are defined as events present at baseline that worsened in intensity after administration of study drug or events absent at baseline that emerged after administration of study drug during the RCP.

Time frame:
Day 1 (Baseline) through Day 197
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs) During RCP
ParticipantsPlacebo/InebilizumabInebilizumab/Inebilizumab
TEAEs41127
TESAEs69
SecondaryNumber of Participants With TEAEs and TESAEs During OLP

An AE is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Serious adverse event is any AE that resulted in death, life threatening, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, is a congenital anomaly/birth defect in offspring of a study participant, is an important medical event that may jeopardize the participant or may require medical intervention. TEAEs are defined as events present at baseline that worsened in intensity after administration of study drug or events absent at baseline that emerged after administration of study drug during the OLP.

Time frame:
Day 198 through end of OLP period (maximum of 3 years after the last participant entered, until regulatory approval or study discontinuation, whichever occurs first) (approximately 3 years)
Reported as:
Count of participants · Participants
Number of Participants With TEAEs and TESAEs During OLP
ParticipantsPlacebo/InebilizumabInebilizumab/Inebilizumab
TEAEs45144
TESAEs1922
SecondaryNumber of Participants With TEAEs and TESAEs During SFP (Open-label Population)

An AE is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Serious adverse event is any AE that resulted in death, life threatening, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, is a congenital anomaly/birth defect in offspring of a study participant, is an important medical event that may jeopardize the participant or may require medical intervention. TEAEs are defined as events present at baseline that worsened in intensity after administration of study drug or events absent at baseline that emerged after administration of study drug during the OLP. Participant who prematurely discontinued from the RCP or OLP entered in the SFP.

Time frame:
Every 3 months for a total of 1 year after the last dose of study drug (approximately 3 years)
Reported as:
Count of participants · Participants
Number of Participants With TEAEs and TESAEs During SFP (Open-label Population)
ParticipantsPlacebo/InebilizumabInebilizumab/Inebilizumab
TEAEs35
TESAEs21
SecondaryNumber of Participants With TEAEs and TESAEs During SFP (Non-OLP Population)

An AE is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Serious adverse event is any AE that resulted in death, life threatening, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, is a congenital anomaly/birth defect in offspring of a study participant, is an important medical event that may jeopardize the participant or may require medical intervention. TEAEs are defined as events present at baseline that worsened in intensity after administration of study drug or events absent at baseline that emerged after administration of study drug during the OLP. The SFP started when a participant prematurely discontinues from the RCP or OLP.

Time frame:
Every 3 months for a total of 1 year after the last dose of study drug (approximately 3 years)
Reported as:
Count of participants · Participants
Number of Participants With TEAEs and TESAEs During SFP (Non-OLP Population)
ParticipantsPlacebo/InebilizumabInebilizumab/Inebilizumab
TEAEs23
TESAEs11
SecondaryNumber of Participants With at Least a 2-Grade Shift From Baseline to Worst Toxicity Grade in Hematology and Chemistry During RCP

Number of participants with at least a 2-grade shift from baseline to worst toxicity grade in hematology and chemistry during RCP is reported.

Time frame:
Day 1 (Baseline) through Day 197
Reported as:
Count of participants · Participants
Number of Participants With at Least a 2-Grade Shift From Baseline to Worst Toxicity Grade in Hematology and Chemistry During RCP
ParticipantsPlacebo/InebilizumabInebilizumab/Inebilizumab
Hemoglobin (decreased)02
Leukocytes (decreased)111
Lymphocytes (decreased)535
Lymphocytes (increased)41
Neutrophils (decreased)010
Alanine Aminotransferase (increased)14
Aspartate Aminotransferase (increased)21
Bilirubin (increased)21
Cholesterol (increased)25
Creatinine (increased)15
Gamma glutamyl transferase (increased)16
Glucose (decreased)11
Glucose (increased)51
Potassium (decreased)01
Sodium (decreased)12
Triglycerides (increased)27
SecondaryNumber of Participants With at Least a 2-Grade Shift From Baseline to Worst Toxicity Grade in Hematology and Chemistry During OLP

Number of participants with at least a 2-grade shift from baseline to worst toxicity grade in hematology and chemistry during OLP is reported.

Time frame:
Day 198 through end of OLP (maximum of 3 years after the last participant enters, until regulatory approval or study discontinuation, whichever occurs first) (approximately 3 years)
Reported as:
Count of participants · Participants
Number of Participants With at Least a 2-Grade Shift From Baseline to Worst Toxicity Grade in Hematology and Chemistry During OLP
ParticipantsPlacebo/InebilizumabInebilizumab/Inebilizumab
Hemoglobin (decreased)26
Leukocytes (decreased)112
Lymphocytes (decreased)921
Lymphocytes (increased)14
Neutrophils (decreased)116
Alanine aminotransferase (increased)42
Albumin (decreased)03
Alkaline phosphatase (increased)11
Aspartate aminotransferase (increased)23
Cholesterol (increased)15
Creatinine (increased)37
Gamma glutamyl transferase (increased)110
Glucose (decreased)03
Glucose (increased)55
Potassium (decreased)01
Potassium (increased)12
Sodium (decreased)21
Triglycerides (increased)46
Urate (increased)11
Hemoglobin (increased)01
Bilirubin20
SecondaryTime to Maximum Serum Concentration (Tmax) of Inebilizumab (During RCP)

Time to maximum serum concentration of inebilizumab during RCP is reported.

Time frame:
Dose 1 (Pre and post dose on Day 1 and Day 8); and Dose 2 (pre and post dose on Day 15; and Days 29, 57, 85, 113, 155, and 197)
Reported as:
Median · Days
Time to Maximum Serum Concentration (Tmax) of Inebilizumab (During RCP)
DaysInebilizumab/Inebilizumab
Dose 10.07 (0.07 to 7.00)
Dose 20.07 (0.07 to 14.00)
SecondaryMaximum Observed Serum Concentration (Cmax) of Inebilizumab (During RCP)

Maximum observed serum concentration of inebilizumab during RCP is reported.

Time frame:
Dose 1 (Pre and post dose on Day 1 and Day 8); and Dose 2 (pre and post dose on Day 15; and Days 29, 57, 85, 113, 155, and 197)
Reported as:
Geometric mean · μg/mL
Maximum Observed Serum Concentration (Cmax) of Inebilizumab (During RCP)
μg/mLInebilizumab/Inebilizumab
Dose 197.7 ± 37.4
Dose 2108 ± 45.4
SecondaryArea Under the Serum Concentration Time Curve of the Dosing Interval (AUC0-14d) of Inebilizumab (During RCP)

Area under the serum concentration time curve of the dosing interval (AUC0-14d) of inebilizumab during RCP is reported.

Time frame:
Dose 1 (Pre and post dose on Day 1 and Day 8); and Dose 2 (pre and post dose on Day 15; and Days 29, 57, 85, 113, 155, and 197)
Reported as:
Geometric mean · μg*d/mL
Area Under the Serum Concentration Time Curve of the Dosing Interval (AUC0-14d) of Inebilizumab (During RCP)
μg*d/mLInebilizumab/Inebilizumab
Dose 1667 ± 31.3
Dose 2967 ± 39.6
SecondaryNumber of Participants With Positive Anti-Drug Antibodies (ADA) Titer to Inebilizumab (During RCP)

Number of participants with positive ADA titer to inebilizumab during RCP is reported.

Time frame:
Pre and post dose on Day 1; and on Days 29, 85, and 197
Reported as:
Count of participants · Participants
Number of Participants With Positive Anti-Drug Antibodies (ADA) Titer to Inebilizumab (During RCP)
ParticipantsPlacebo/InebilizumabInebilizumab/Inebilizumab
ADA positive at anytime including baseline (BL)817
ADA positive at BL; not detected post-BL05
ADA positive post-BL; positive at BL47
ADA positive post-BL; not detected at BL45
SecondaryNumber of Participants With Positive Anti-Drug Antibodies (ADA) Titer to Inebilizumab (During OLP)

Number of participants with positive ADA titer to inebilizumab in OLP is reported.

Time frame:
Pre and post dose on Day 1; and on Days 92, 183, 274, and then every 6 months (maximum of 3 years after the last participant enters, until regulatory approval or study discontinuation, whichever occurs first) (approximately 3 years)
Reported as:
Count of participants · Participants
Number of Participants With Positive Anti-Drug Antibodies (ADA) Titer to Inebilizumab (During OLP)
ParticipantsPlacebo/InebilizumabInebilizumab/Inebilizumab
ADA positive at any time including baseline (BL)922
ADA positive at BL; not detected post-BL05
ADA positive post-BL and positive at BL47
ADA positive post-BL; not detected at BL510

Adverse events

Collected over From Day 1 through the end of study (approximately 5 years 10 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo/Inebilizumab1/56 (1.8%)24/56 (42.9%)48/56 (85.7%)
Inebilizumab/Inebilizumab2/174 (1.1%)28/174 (16.1%)138/174 (79.3%)
Most frequent serious events
Showing 10 of 88
Most frequent serious events
EventPlacebo/InebilizumabInebilizumab/Inebilizumab
Urinary tract infectionInfections and infestations7/563/174
PneumoniaInfections and infestations3/563/174
HyponatraemiaMetabolism and nutrition disorders2/560/174
Muscular weaknessMusculoskeletal and connective tissue disorders2/560/174
Neuromyelitis optica spectrum disorderNervous system disorders2/563/174
Acute kidney injuryRenal and urinary disorders2/560/174
Hepatic failureHepatobiliary disorders1/560/174
HypoglycaemiaMetabolism and nutrition disorders1/560/174
Back painMusculoskeletal and connective tissue disorders1/561/174
Visual acuity reducedEye disorders1/560/174
Most frequent other events
Showing 10 of 44
Most frequent other events
EventPlacebo/InebilizumabInebilizumab/Inebilizumab
Urinary tract infectionInfections and infestations20/5640/174
HeadacheNervous system disorders13/5631/174
NasopharyngitisInfections and infestations11/5638/174
ArthralgiaMusculoskeletal and connective tissue disorders12/5628/174
Upper respiratory tract infectionInfections and infestations10/5628/174
NauseaGastrointestinal disorders9/5615/174
Infusion related reactionInjury, poisoning and procedural complications9/5622/174
Pain in extremityMusculoskeletal and connective tissue disorders9/5611/174
DiarrhoeaGastrointestinal disorders8/5615/174
Back painMusculoskeletal and connective tissue disorders8/5624/174

Baseline characteristics

The Intent-to-treat (ITT) population included all participants who were randomized, received any study drug, and grouped according to their randomized treatment.

Age, Continuous
Age, Continuous(Years)Placebo/InebilizumabInebilizumab/InebilizumabTotal
Mean42.6 ± 13.943.0 ± 11.642.9 ± 12.2
Sex: Female, Male
Sex: Female, Male(Participants)Placebo/InebilizumabInebilizumab/InebilizumabTotal
Female50159209
Male61521
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Placebo/InebilizumabInebilizumab/InebilizumabTotal
Hispanic or Latino152843
Not Hispanic or Latino41146187
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Placebo/InebilizumabInebilizumab/InebilizumabTotal
American Indian or Alaska Native51419
Asian83947
Native Hawaiian or Other Pacific Islander000
Black or African American51520
White2892120
More than one race011
Unknown or Not Reported101323
08

Study locations

98 sites
  • Research Site
    Birmingham, Alabama 35294, United States
  • Research Site
    Sacramento, California 95817, United States
  • Research Site
    San Francisco, California 94158, United States
  • Research Site
    Aurora, Colorado 80010, United States
  • Research Site
    New Haven, Connecticut 06511, United States
  • Research Site
    Maitland, Florida 32751, United States
  • Research Site
    Chicago, Illinois 60637, United States
  • Research Site
    Kansas City, Kansas 66160, United States
  • Research Site
    Baltimore, Maryland 21287, United States
  • Research Site
    Detroit, Michigan 48201, United States
  • Research Site
    Rochester, Minnesota 55905, United States
  • Research Site
    Saint Louis, Missouri 63131-2374, United States
  • Research Site
    Raleigh, North Carolina 27607, United States
  • Research Site
    Cincinnati, Ohio 45219, United States
  • Research Site
    Cleveland, Ohio 44195, United States
  • Research Site
    Mansfield, Ohio 44906, United States
  • Research Site
    Dallas, Texas 75390, United States
  • Research Site
    Houston, Texas 77030, United States
  • Research Site
    Richmond, Virginia 23298, United States
  • Research Site
    Melbourne, 3065, Australia
  • Research Site
    Sofia, 1113, Bulgaria
  • Research Site
    Sofia, 1309, Bulgaria
  • Research Site
    Sofia, 1431, Bulgaria
  • Research Site
    Varna, 9010, Bulgaria
  • Research Site
    Vancouver, British Columbia V6T 2B5, Canada
  • Research Site
    Barranquilla, 080020, Colombia
  • Research Site
    Bogota, 110131, Colombia
  • Research Site
    Bogota, 110231, Colombia
  • Research Site
    Cali, 760032, Colombia
  • Research Site
    Olomouc, 775 20, Czechia
  • Research Site
    Praha 2, 121 11, Czechia
  • Research Site
    Teplice, 415 29, Czechia
  • Research Site
    Tallinn, 10617, Estonia
  • Research Site
    Tartu, 51014, Estonia
  • Research Site
    Berlin, 10117, Germany
  • Research Site
    Dresden, 01307, Germany
  • Research Site
    Düsseldorf, 40225, Germany
  • Research Site
    Leipzig, 04103, Germany
  • Research Site
    Muenster, 48149, Germany
  • Research Site
    Rostock, 18147, Germany
  • Research Site
    HongKong, Hong Kong
  • Research Site
    Esztergom, 2500, Hungary
  • Research Site
    Nyíregyháza, 4400, Hungary
  • Research Site
    Szeged, 6725, Hungary
  • Research Site
    Jerusalem, 91120, Israel
  • Research Site
    Ramat Gan, 52621, Israel
  • Research Site
    Tel Aviv, 6423906, Israel
  • Research Site
    Aomori-shi, 030-8553, Japan
  • Research Site
    Bunkyo-ku, 113-8431, Japan
  • Research Site
    Kyoto-shi, 604-8453, Japan
  • Research Site
    Ota-ku, 145-0065, Japan
  • Research Site
    Sendai-shi, 980-8574, Japan
  • Research Site
    Tsukuba, 305-8577, Japan
  • Research Site
    Goyang, 410-769, Korea, Republic of
  • Research Site
    Jongno-gu, 110-744, Korea, Republic of
  • Research Site
    Seoul, 135-710, Korea, Republic of
  • Research Site
    Seoul, 143729, Korea, Republic of
  • Research Site
    Ciudad De Mexico, 14269, Mexico
  • Research Site
    Mexico City, 03310, Mexico
  • Research Site
    Monterrey, 64460, Mexico
  • Research Site
    San Luis Potosi, 78090, Mexico
  • Research Site
    Chisinau, 2028, Moldova, Republic of
  • Research Site
    Auckland, 1023, New Zealand
  • Research Site
    Bellavista, CALLAO 2, Peru
  • Research Site
    Lima, LIMA 01, Peru
  • Research Site
    Katowice, 40-595, Poland
  • Research Site
    Krakow, 31-637, Poland
  • Research Site
    Lublin, 20-954, Poland
  • Research Site
    Lódz, 90-324, Poland
  • Research Site
    Olsztyn, 10-560, Poland
  • Research Site
    Warszawa, 02-097, Poland
  • Research Site
    Warszawa, 02-957, Poland
  • Research Site
    Belgorod, 308007, Russian Federation
  • Research Site
    Kazan, 420021, Russian Federation
  • Research Site
    Khabarovsk, 680009, Russian Federation
  • Research Site
    Krasnoyarsk, 660037, Russian Federation
  • Research Site
    Moscow, 123367, Russian Federation
  • Research Site
    Moscow, 127018, Russian Federation
  • Research Site
    Nizhniy Novgorod, 603155, Russian Federation
  • Research Site
    Novosibirsk, 63007, Russian Federation
  • Research Site
    Omsk, 644033, Russian Federation
  • Research Site
    Saint-Petersburg, 197110, Russian Federation
  • Research Site
    Ufa, 450005, Russian Federation
  • Research Site
    Belgrade, 11129, Serbia
  • Research Site
    Cape Town, 7505, South Africa
  • Research Site
    Cape Town, 7925, South Africa
  • Research Site
    Madrid, 28040, Spain
  • Research Site
    Changhua City, 50006, Taiwan
  • Research Site
    Hualien City, 97002, Taiwan
  • Research Site
    Tainan City, 70403, Taiwan
  • Research Site
    Bangkok, 10700, Thailand
  • Research Site
    Muang, 40002, Thailand
  • Research Site
    Muang, 50200, Thailand
  • Research Site
    Istanbul, 34098, Turkey
  • Research Site
    Istanbul, 34147, Turkey
  • Research Site
    Istanbul, 34890, Turkey
  • Research Site
    Izmir, 35170, Turkey
  • Research Site
    Samsun, 55139, Turkey
09

References and documents

Publications

  • Bennett JL, Aktas O, Rees WA, Smith MA, Gunsior M, Yan L, She D, Cimbora D, Pittock SJ, Weinshenker BG, Paul F, Marignier R, Wingerchuk D, Cutter G, Green A, Hartung HP, Kim HJ, Fujihara K, Levy M, Katz E, Cree BAC; N-MOmentum study investigators. Association between B-cell depletion and attack risk in neuromyelitis optica spectrum disorder: An exploratory analysis from N-MOmentum, a double-blind, randomised, placebo-controlled, multicentre phase 2/3 trial. EBioMedicine. 2022 Dec;86:104321. doi: 10.1016/j.ebiom.2022.104321. Epub 2022 Nov 10. PubMed 36370634 ↗
  • Flanagan EP, Levy M, Katz E, Cimbora D, Drappa J, Mealy MA, She D, Cree BAC. Inebilizumab for treatment of neuromyelitis optica spectrum disorder in patients with prior rituximab use from the N-MOmentum Study. Mult Scler Relat Disord. 2022 Jan;57:103352. doi: 10.1016/j.msard.2021.103352. Epub 2021 Oct 26. PubMed 35158461 ↗
  • Marignier R, Bennett JL, Kim HJ, Weinshenker BG, Pittock SJ, Wingerchuk D, Fujihara K, Paul F, Cutter GR, Green AJ, Aktas O, Hartung HP, Lublin FD, Williams IM, Drappa J, She D, Cimbora D, Rees W, Smith M, Ratchford JN, Katz E, Cree BAC; N-MOmentum Study Investigators. Disability Outcomes in the N-MOmentum Trial of Inebilizumab in Neuromyelitis Optica Spectrum Disorder. Neurol Neuroimmunol Neuroinflamm. 2021 Mar 26;8(3):e978. doi: 10.1212/NXI.0000000000000978. Print 2021 May. PubMed 33771837 ↗
  • Aktas O, Smith MA, Rees WA, Bennett JL, She D, Katz E, Cree BAC; N-MOmentum scientific group and the N-MOmentum study investigators. Serum Glial Fibrillary Acidic Protein: A Neuromyelitis Optica Spectrum Disorder Biomarker. Ann Neurol. 2021 May;89(5):895-910. doi: 10.1002/ana.26067. Epub 2021 Mar 30. PubMed 33724534 ↗
  • Cree BA, Bennett JL, Kim HJ, Weinshenker BG, Pittock SJ, Wingerchuk D, Fujihara K, Paul F, Cutter GR, Marignier R, Green AJ, Aktas O, Hartung HP, Williams IM, Drappa J, She D, Cimbora D, Rees W, Ratchford JN, Katz E. Sensitivity analysis of the primary endpoint from the N-MOmentum study of inebilizumab in NMOSD. Mult Scler. 2021 Nov;27(13):2052-2061. doi: 10.1177/1352458521988926. Epub 2021 Feb 4. PubMed 33538237 ↗
  • Cree BAC, Bennett JL, Kim HJ, Weinshenker BG, Pittock SJ, Wingerchuk DM, Fujihara K, Paul F, Cutter GR, Marignier R, Green AJ, Aktas O, Hartung HP, Lublin FD, Drappa J, Barron G, Madani S, Ratchford JN, She D, Cimbora D, Katz E; N-MOmentum study investigators. Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial. Lancet. 2019 Oct 12;394(10206):1352-1363. doi: 10.1016/S0140-6736(19)31817-3. Epub 2019 Sep 5. PubMed 31495497 ↗
  • Cree BA, Bennett JL, Sheehan M, Cohen J, Hartung HP, Aktas O, Kim HJ, Paul F, Pittock S, Weinshenker B, Wingerchuk D, Fujihara K, Cutter G, Patra K, Flor A, Barron G, Madani S, Ratchford JN, Katz E. Placebo-controlled study in neuromyelitis optica-Ethical and design considerations. Mult Scler. 2016 Jun;22(7):862-72. doi: 10.1177/1352458515620934. Epub 2015 Dec 14. PubMed 26666258 ↗

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2015 to primary completion in Oct 2018, 42 months.

Results were first posted in Dec 2019, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 16, 2014
First posted
Jul 25, 2014
StartActual
Apr 1, 2015
Primary completionActual
Oct 26, 2018
CompletionActual
Nov 6, 2020
Results first posted
Dec 26, 2019
Last update
Dec 3, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 3, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02200770
Lead sponsor
MedImmune LLC
Responsible party
Sponsor
First posted
Jul 25, 2014
Start date
Apr 1, 2015
Primary completion
Oct 26, 2018
Completion
Nov 6, 2020
Results posted
Dec 26, 2019
Last update
Dec 3, 2021

Study contacts

MedImmune, LLC MedImmune, LLC
study director · MedImmune LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Inebilizumab

Start the discussion